Botswana Harvard AIDS Institute Partnership , Gaborone, Botswana.
Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana , Gaborone, Botswana.
Microbiol Spectr. 2023 Dec 12;11(6):e0125123. doi: 10.1128/spectrum.01251-23. Epub 2023 Oct 12.
Fostemsavir (FTR) is a newly licensed antiretroviral drug that has been shown to have activity against HIV-1. The mechanism of action of FTR is different from all currently available antiretrovirals (ARVs), and as such, it offers hope for HIV-1 suppression in those people with HIV (PWH) who harbor HIV-1 variants with drug resistance mutations to currently used ARVs. Using 6,030 HIV-1 sequences covering the HIV-1 envelope from PWH in Botswana who are antiretroviral therapy (ART) naïve as well as those who are failing ART, we explored the sequences for FTR resistance-associated polymorphisms. We found the prevalence of FTR polymorphisms to be similar in both ART-naïve and ART-experienced individuals with VF in this setting, with no prior FTR exposure. Further studies on the phenotypic impact of these polymorphisms are warranted to guide how to monitor for FTR resistance.
福替司韦（FTR）是一种新获得许可的抗逆转录病毒药物，已被证明对 HIV-1 具有活性。FTR 的作用机制与目前所有可用的抗逆转录病毒药物（ARV）不同，因此，它为那些携带对目前使用的 ARV 具有耐药突变的 HIV-1 变异体的 HIV 感染者（PWH）提供了 HIV-1 抑制的希望。我们使用了来自博茨瓦纳接受抗逆转录病毒治疗（ART）的初治和治疗失败的 HIV-1 感染者的 6030 个 HIV-1 序列，涵盖了 HIV-1 包膜，探索了与 FTR 耐药相关的多态性。我们发现，在这种情况下，无先前 FTR 暴露的情况下，初治和治疗失败的 VF 个体中 FTR 多态性的流行率相似。需要进一步研究这些多态性的表型影响，以指导如何监测 FTR 耐药。
